Publication:
Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients

Simple item page
dc.contributor.authorS Fadilah Abdul Wahid
dc.contributor.authorNor Azimah Ismail
dc.contributor.authorWan Fariza Wan Jamaludin
dc.contributor.authorNor Asiah Muhamad
dc.contributor.authorMuhammad Khairul Azaham Abdul Hamid
dc.contributor.authorHanafiah Harunarashid
dc.contributor.authorNai Ming Lai
dc.date.accessioned2024-08-07T03:13:54Z
dc.date.available2024-08-07T03:13:54Z
dc.date.issued2018
dc.description.abstractBackground: Revascularisation is the gold standard therapy for patients with critical limb ischaemia (CLI). In over 30% of patients who are not suitable for or have failed previous revascularisation therapy (the 'no-option' CLI patients), limb amputation is eventually unavoidable. Preliminary studies have reported encouraging outcomes with autologous cell-based therapy for the treatment of CLI in these 'no-option' patients. However, studies comparing the angiogenic potency and clinical e'ects of autologous cells derived from di'erent sources have yielded limited data. Data regarding cell doses and routes of administration are also limited. Objectives: To compare the e'icacy and safety of autologous cells derived from di'erent sources, prepared using di'erent protocols, administered at di'erent doses, and delivered via di'erent routes for the treatment of 'no-option' CLI patients. Search methods: The Cochrane Vascular Information Specialist (CIS) searched the Cochrane Vascular Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINEOvid, EmbaseOvid,the Cumulative Index toNursing and AlliedHealth Literature (CINAHL),the Allied and Complementary Medicine Database (AMED), and trials registries (16 May 2018). Review authors searched PubMed until February 2017. Selection criteria: We included randomised controlled trials (RCTs) involving 'no-option' CLI patients comparing a particular source orregimen of autologous cell-based therapy against another source or regimen of autologous cell-based therapy. Data collection and analysis: Three review authors independently assessed the eligibility and methodological quality ofthe trials.We extracted outcome data from each trial and pooled them for meta-analysis. We calculated e'ect estimates using a risk ratio (RR) with 95% confidence interval (CI), or a mean di'erence (MD) with 95% CI.
dc.identifier.doi10.1002/14651858.CD010747.pub2
dc.identifier.urihttps://repository.nih.gov.my/handle/123456789/873
dc.language.isoen
dc.publisherJohn Wiley & Sons, Ltd.
dc.relation.ispartofCochrane Database of Systematic Reviews
dc.relation.journalCochrane Database of Systematic Reviews
dc.titleAutologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients
dc.typejournal-article
dspace.entity.typePublication
oaire.citation.issue8
oaire.citation.volume2018
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
46.Autologous cells derived_Dr Nor Asiah.pdf
Size:
974.44 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Selected Article of Journal (IKU)